Wednesday, June 06, 2012 7:09:09 PM
Ixmyelocel-T Shown to Protect Heart From Damage in Murine Model of Heart Failure
Data Showing Treatment With Ixmyelocel-T Resulted in Decreased Infarct Size Presented in Poster Presentation at the 18th Annual International Society for Cellular Therapy Meeting
GlobeNewswirePress Release: Aastrom Biosciences, Inc.
ANN ARBOR, Mich., June 6, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM - News), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced results from a preclinical study demonstrating the ability of ixmyelocel-T to protect the ischemic heart from damage in a murine model of heart failure. Results were presented at the 18th Annual International Society for Cellular Therapy Meeting in a poster presentation entitled "Ixmyelocel-T protects the heart from damage in a murine model of heart failure."
In a blinded, vehicle-controlled study, a murine model of non-acute left anterior descending (LAD) coronary artery occlusion was used to evaluate ixmyelocel-T as a potential treatment for dilated cardiomyopathy (DCM). Hearts were analyzed four weeks following injection and those in the treated group experienced a significant decrease in infarct length compared to the vehicle control group. The results were consistent between two lots of ixmyelocel-T (Lot 1: 2.72+/- 0.77 vs. 6.14+/- 0.43, P<0.001; Lot 2: 3.80+/- 0. 37 vs. 7.34+/- 0.47, P<0.001). Animals treated with ixmyelocel-T demonstrated a reduced mortality compared to control (22% vs. 44%) and decreased infarct size and increased survival when compared to a vehicle control group.
Ixmyelocel-T therapy is a patient-specific, expanded multicellular therapy comprised of a mixture of cell types cultured from bone marrow mononuclear cells (BMMNCs). Early studies have shown ixmyelocel-T may have positive effects on activities such as tissue remodeling, immunomodulation and the promotion of angiogenesis, which can contribute to severe, chronic cardiovascular diseases.
DCM is a progressive disease of heart muscle. It is the third most common cause of heart failure and the most frequent cause of heart transplantation. The ability of ixmyelocel-T to promote tissue salvage in preclinical trials indicates that the therapy may be protective to the ischemic heart, a cause of DCM. There is currently no accepted preclinical model for DCM.
Recent VCEL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:05:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/13/2024 08:13:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/12/2024 08:18:41 PM
- Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024 • GlobeNewswire Inc. • 06/11/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:05:33 PM
- Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024 • GlobeNewswire Inc. • 05/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:07:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:05:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2024 04:15:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 08:05:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/16/2024 02:43:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2024 05:10:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 12:59:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 12:10:26 PM
- Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance • GlobeNewswire Inc. • 05/08/2024 11:55:00 AM
- Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024 • GlobeNewswire Inc. • 04/24/2024 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 08:15:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:08:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:07:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 10:12:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/07/2024 08:35:28 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 02:04:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:04:33 PM
- Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance • GlobeNewswire Inc. • 02/29/2024 12:55:00 PM
- Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM